Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$8.95 - $12.8 $779,285 - $1.11 Million
-87,071 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$10.05 - $22.48 $47,596 - $106,465
4,736 Added 5.75%
87,071 $1.08 Million
Q4 2021

Feb 14, 2022

SELL
$17.78 - $33.08 $4.36 Million - $8.12 Million
-245,436 Reduced 74.88%
82,335 $1.88 Million
Q2 2020

Aug 14, 2020

BUY
$14.12 - $18.33 $1.54 Million - $2 Million
109,000 Added 49.82%
327,771 $5.33 Million
Q1 2020

May 15, 2020

SELL
$11.34 - $21.46 $2.97 Million - $5.63 Million
-262,333 Reduced 54.53%
218,771 $3.17 Million
Q4 2019

Jan 31, 2020

BUY
$3.88 - $21.42 $1.87 Million - $10.3 Million
481,104 New
481,104 $9.75 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.13B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.